Pediatrix Medical Group, Inc. (NYSE:MD) Shares Bought by Swiss National Bank

Swiss National Bank lifted its holdings in shares of Pediatrix Medical Group, Inc. (NYSE:MD) by 2.8% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 168,900 shares of the company’s stock after purchasing an additional 4,600 shares during the quarter. Swiss National Bank’s holdings in Pediatrix Medical Group were worth $2,216,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Pacer Advisors Inc. acquired a new position in Pediatrix Medical Group during the 4th quarter worth $35,492,000. Weiss Asset Management LP increased its stake in shares of Pediatrix Medical Group by 50.5% during the third quarter. Weiss Asset Management LP now owns 912,818 shares of the company’s stock worth $10,580,000 after buying an additional 306,143 shares during the period. Raymond James Financial Inc. acquired a new stake in Pediatrix Medical Group in the fourth quarter valued at approximately $3,066,000. RBF Capital LLC purchased a new position in Pediatrix Medical Group in the third quarter worth approximately $1,695,000. Finally, Algert Global LLC acquired a new position in Pediatrix Medical Group during the 3rd quarter worth approximately $1,315,000. Hedge funds and other institutional investors own 97.71% of the company’s stock.

Pediatrix Medical Group Stock Performance

Shares of MD stock opened at $15.06 on Friday. The stock’s 50-day moving average is $14.39 and its two-hundred day moving average is $13.62. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.42 and a current ratio of 1.60. Pediatrix Medical Group, Inc. has a 1 year low of $6.62 and a 1 year high of $17.67. The firm has a market cap of $1.29 billion, a price-to-earnings ratio of -12.55, a PEG ratio of 1.74 and a beta of 1.49.

Pediatrix Medical Group (NYSE:MD) last released its quarterly earnings results on Thursday, February 20th. The company reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.12. Pediatrix Medical Group had a positive return on equity of 15.47% and a negative net margin of 4.92%. The firm had revenue of $502.36 million for the quarter, compared to the consensus estimate of $486.22 million. Analysts predict that Pediatrix Medical Group, Inc. will post 1.38 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. Macquarie initiated coverage on shares of Pediatrix Medical Group in a research report on Monday, December 16th. They set an “outperform” rating and a $18.00 price objective for the company. StockNews.com upgraded Pediatrix Medical Group from a “hold” rating to a “buy” rating in a research note on Wednesday, January 22nd. Truist Financial upped their price objective on Pediatrix Medical Group from $15.00 to $18.00 and gave the stock a “hold” rating in a research report on Friday, February 21st. Finally, UBS Group raised their target price on Pediatrix Medical Group from $16.50 to $18.50 and gave the stock a “neutral” rating in a research report on Friday, February 21st. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $17.08.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.